Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction

Leppert, Wojciech

doi:10.2174/13894501113149990210

Cited by 30 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial dose should be titrated to achieve effective analgesia and acceptable adverse effects. Currently, OXN is approved in daily doses of up to 80/40 mg (16); however, controlled studies in patients with nonmalignant (17) and cancer-related pain (18) demonstrated that the daily dose of 120/60 mg might be safe and effective. On the other hand, Mercadante et al (19) reported a patient with severe cancer pain, which required high daily doses of OXN (240/120 mg) that were ineffective.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Failed Back Surgery Syndrome in a Forty-Three-Year-Old Man With High-Dose Oxycodone/Naloxone

Bujedo

2015

Anesth Pain Med

View full text Add to dashboard Cite

Introduction:Failed back surgery syndrome (FBSS) is an increasing cause of chronic pain in most countries. This poses high costs to both patients and National Health Organizations.Case Presentation:In this report, multimodal pain management based on daily high-dose oxycodone/naloxone (OXN 180/90 mg) led to reduced patient's pain score and improved quality of life.Conclusions:Oxycodone/naloxone can be a good alternative for the management of FBSS when other interventional or pharmacologic strategies have failed. In this case report, higher doses than those recommended as a maximum daily ceiling (80/40 mg) were safely used in one selected patient with noncancer severe pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Failed Back Surgery Syndrome in a Forty-Three-Year-Old Man With High-Dose Oxycodone/Naloxone

Bujedo

2015

Anesth Pain Med

View full text Add to dashboard Cite

show abstract

“…The available OXY/NLX doses are in a ratio of 2:1 with 5/2.5 mg, 10/5 mg, 20/10 mg, and 40/20 mg [ 77 ]. The optimal 2:1 ratio was reported in a four-arm clinical trial ( N = 202) where subjects were treated with OXY dosed 40 and 80 mg daily and NLX with varying doses of 0, 10, 20, and 40 mg [ 78 ].…”

Section: Oxycodone (Oxy)/naloxone (Nlx)mentioning

confidence: 99%

“…[ 82 ]. Clinicians should constantly monitor patients using this product for both chronic pain management and constipation pharmacotherapy [ 77 ].…”

Section: Oxycodone (Oxy)/naloxone (Nlx)mentioning

confidence: 99%

Anti-addiction Agents

Jann

2016

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

View full text Add to dashboard Cite

Pharmacotherapeutic interventions for addiction focus on treatment and prevention of dependence. Addiction is a complex biological process and its complete underlying pathophysiology remains elusive. Successful treatment involves both short-term and long-term maintenance pharmacologic approaches linked with various psychosocial support avenues. However, specifi c agents have been developed for alcohol, nicotine, and opiate dependence. Disulfi ram has been used since the 1950s as an aversive therapeutic technique where its metabolites when exposed to alcohol lead to the patient experiencing symptoms of nausea and vomiting, encouraging the patient to abstain from alcohol. Acamprosate is indicated for alcohol abstinence maintenance with the chemical component acetyl-homotaurine measured in pharmacokinetic studies. Acamprosate is primarily renally excreted. Varenicline is a partial agonist of the central nicotinic acetylcholine receptor and approved for the treatment of nicotine dependence. Varenicline is mainly renally excreted where a combined pharmacokinetic-pharmacodynamic model described this compound with an open two-compartment pharmacokinetic model with a linear pharmacodynamic model. Naloxone and naltrexone are opiate antagonists used in a variety of clinical settings. Naloxone is a "rescue" agent for opiate overdose. Naltrexone is used for alcohol dependence and available in an oral and a monthly long-acting depot injection. Naloxone has been combined with pentazocine, buprenorphine, and oxycodone to prevent abuse. Levo-alpha acetyl methadol (LAAM) is a potent derivative of methadone but QTc prolongation occurrences have limited its clinical use.

show abstract

“…In four published studies, two showed equivocal results. However, two studies documented significant improvement in postoperative bowel functions, one also improved the passing of urine, an often neglected adverse effect of postoperative pain treatment with opioids [11][12][13]. The study by Comelon and co-workers [13] on bowel functions after laparoscopic hysterectomies did not find effects on postoperative bowel function when comparing OxyContin ® 10 mg without naloxone with OxyContin ® 10 mg with 5 mg naloxone added (= Targin ® , Targiniq ® , Targinact ® ) twice daily.…”

Section: Oral Prolonged Release Naloxonementioning

confidence: 99%

Oral immediate and prolonged release oxycodone for safe and effective patient controlled analgesia after surgery Can opioid for acute postoperative pain be improved by adding a peripheral opioid antagonist?

Ræder

Breivik

2015

Scandinavian Journal of Pain

View full text Add to dashboard Cite

Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction

Abstract: OXN is an important drug for chronic pain management, prevention and treatment of OIBD.

Cited by 30 publications

References 0 publications

Treatment of Failed Back Surgery Syndrome in a Forty-Three-Year-Old Man With High-Dose Oxycodone/Naloxone

Treatment of Failed Back Surgery Syndrome in a Forty-Three-Year-Old Man With High-Dose Oxycodone/Naloxone

Anti-addiction Agents

Oral immediate and prolonged release oxycodone for safe and effective patient controlled analgesia after surgery Can opioid for acute postoperative pain be improved by adding a peripheral opioid antagonist?

Contact Info

Product

Resources

About